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Black salve is a topical escharotic used for the treatment of skin cancer. Although promoted as a safe and effective alternative
to conventional management by its proponents, limited clinical research has been undertaken to assess its efficacy and potential
toxicities. Patients are increasingly utilizing the Internet as a source of health information. As a minimally regulated space, the
quality and accuracy of this information vary considerably. This review explores four health claims made by black salve vendors,
investigating its natural therapy credentials, tumour specificity, and equivalence to orthodox medicine in relation to skin cancer
cure rates and cosmesis. Based upon an analysis of in vitro constituent cytotoxicity, in vivo post black salve histology, and experience
with Mohs paste, black salve is likely to possess normal tissue toxicity with some cancer cell lines being relatively resistant to its
effects. This may explain the incongruous case study reports of excessive scarring, deformity, and treatment failure.
1. Introduction
Complementary and alternative medicines (CAM) encom-
pass a wide range of popular health interventions [1]. Self-
reported use of CAM from surveys across North America,
Europe, and Australia shows a high level of use with 35 to
69% of respondents having used CAM in the preceeding 12
months [2–4].
Patients with dermatological conditions more heavily
utilize CAM than the general population, with 12-month
prevalence figures of 49% versus 36% in 2002 [5] and 85%
versus 38% in 2007 [6].Despite conventional therapies having
high cure rates for skin malignancies, a number of patients
are opting to manage their skin cancers with CAM [7]. While
the extent of this practice is yet to be determined, patients
are motivated by a preference for natural therapies and a
perception of lower toxicity for CAM compared to orthodox
treatment modalities [8].
Despite questions regarding the effectiveness of CAM
therapies [9] and their general lack of systematic scientific
testing [10], herbal medicines should not be dismissed with-
out consideration. Natural products have been a vital source
of anticancer pharmaceuticals, with 49% of oncology small
molecules discovered since 1940 being either unaltered or
direct derivatives of natural compounds [11]. Due to the
molecular diversity and structural complexity of natural
products compared to synthetic compound libraries, there is
renewed interest in natural product drug discovery [12].
Concerns however exist about the lack of regulatory
control over the natural therapy sector and how this impacts
quality control and patient safety [13]. Although used as
medicines, regulators in some countries treat herbal therapies
as dietary supplements [14]. Unlike pharmaceutical products,
manufacturers are not always required to provide safety or
efficacy evidence to regulators before their product can be
sold to patients [15]. To better inform clinicians and patients,
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this literature review seeks to assess some of the health claims
made regarding black salve.
2. Black Salve as a Natural Therapy
Black salvewas originally developed by anAmerican surgeon,
Jesse Fell, its use first reported in the 1850s [16]. Fell had
heard of a plant growing on the shores of Lake Superior used
by Native Americans to treat cancer (reviewed in [17]). He
identified it as S. canadensis, combining it with zinc chloride
to make a cancer salve known as Fells’ paste [18]. Since then,
other entrepreneurs have developed topical cancer therapies
based on these two core ingredients, today's formulations
being known as black salve [19].
Referred to as “Natures Scalpel” [20], it is important
to assess the veracity of black salves’ natural credentials.
Consumers often believe natural therapies are safe, having the
ability to heal with a low risk of toxicity [21]. Portraying black
salve as a natural product appeals to this naturalness bias,
which in turn may increase black salve utilization by CAM
users.
Black salves usually contain bloodroot, the rhizome of
Sanguinaria canadensis. Manufacturers have differing for-
mulations that may also contain chaparral (Larrea mexi-
cana), graviola (Annona muricata), oleander (Nerium olean-
der), galangal (Alpinia officinarum), ginger (Zingiber offici-
nale), red clover (Trifolium pratense), sheep sorrel (Rumex
acetosella), burdock (Arctium lappa), pokeroot (Phytolacca
decandra), and turmeric (Curcuma longa) [22–25].
Apart from its botanical ingredients, black salve con-
tains zinc chloride (ZnCl2) with some formulations also
containing dimethyl sulfoxide (DMSO). ZnCl2is a chemical
usually manufactured from zinc and hydrochloric acid and
does not occur naturally apart from the very rare mineral
simonkolleite Zn5(OH)8Cl2H2O [26]. ZnCl2 is widely used
for industrial processes such as textile manufacture and
metallurgical fluxes for soldering galvanized iron [27]. The
ZnCl2 contained in black salve is a synthesized chemical and
in some preparations the main ingredient by weight [28].
DMSO is added to enhance the epidermal penetration
of some black salve formulations. Although trace amounts
of DMSO may be naturally found in cereals, fruits, and
vegetables [29], DMSO is commercially manufactured from
lignin, a byproduct of paper production [30]. DMSOs’ chem-
ical synthesis utilizes lignins free methyl radicals; these are
coupled to sulphur and then oxidized [31].
Patients seeking natural skin cancer therapies may not
realize black salve contains significant quantities of synthetic
chemicals. This knowledge may alter the treatment choices
of CAM patients, a population often wanting to reduce their
exposure to unnatural compounds [56].
3. Black Salve Cancer Specificity and
Normal Tissue Toxicity
Black salve is promoted as a safe skin cancer therapy, able
to discriminate between cancerous and healthy tissue [57].
There are concerns about the accuracy of this claimwith cases
of extensive tissue necrosis reported in the literature from
black salve use [38, 58]. Two explanations may account for
this finding. Treated cancers were more extensive than they
appeared clinically, or, in addition to having a destructive
effect on malignant tissue, black salve can also cause normal
tissue necrosis.
As a therapeutic product containing multiple bioactive
compounds, the discriminating ability of black salve can be
gauged by the cytotoxic potential of its individual constitu-
ents againstmalignant and normal cells. S. canadensis, known
as bloodroot because of the red latex of its rhizome, is an
important component of black salve [17]. Native Americans
called the plant puccoon and used it as a traditional medicine
to treat a variety of conditions including cancer [18].
Bloodroot rhizomes predominantly contain a number of
quaternary benzophenanthridine alkaloids (QBA) in addi-
tion to protopin alkaloids [59]. These plant defence toxins
target multiple cellular pathways [60], being able to interca-
late with DNA [61] and RNA [62–64], alter gene expression
through the epigenetic modification of chromatin and core
histones [65], inhibit microtubules needed for cell division
[66], and generate oxidative stress [67].
Several studies have compared the antiproliferative and
cytotoxic effects of these alkaloids against normal and
malignant cells in vitro. In 2000, Ahmad et al. reported
that sanguinarine had preferential, concentration dependent
tumour cytotoxicity when tested against the A431 epider-
moid carcinoma cell line and normal human epidermal
keratinocytes derived from foreskin. At 2 𝜇M, sanguinarine
induced 60% cytotoxicity in A431 cells compared to 10.8%
in normal keratinocytes. However 5 𝜇M sanguinarine caused
65% cytotoxicity in A431 cells compared to 38.3% in normal
keratinocytes representing a loss of discrimination [34].
Contradictory results however have shown sanguinarine
to have greater cytotoxicity against normal skin fibroblasts
compared to the same A431 squamous cancer cell line [32].
This suggests that sensitivity to sanguinarine cytotoxicity
depends more on target cell characteristics than whether the
exposed cells are malignant or benign. After 24-hour expo-
sure to the two main bloodroot alkaloids sanguinarine and
chelerythrine gingival fibroblasts have shown low IC50 values
of 1.2 𝜇Mand 4.7 𝜇M, respectively [33, 68] (Figure 1). Various
cancer cell lines in these studies showed greater resistance
to sanguinarine cytotoxicity than nonmalignant cells, further
undermining the argument that sanguinarine has tumour
specific cytotoxicity. Similar results from four biologically
active S. canadensis minor quaternary benzophenanthridine
alkaloids (minor QBAs) also frequently showed greater non-
malignant cell cytotoxicity (Figure 2).
Themechanism of sanguinarine cytotoxicity has not been
fully elucidated and appears to vary for different cell types. In
squamous carcinoma cells, sanguinarine induces cell death by
apoptosis, while, in keratinocytes, sanguinarine induces cell
death by necrosis [34]. Several apoptotic molecular pathways
have been implicated such as caspase 3 and 7 activation in
PC3 prostate cancer cells, rapid GSH depletion in murine
L929 fibroblasts [68], and reduced bcl-2 with increased BH3
interacting domain death agonist (Bid) and proapoptotic B
cell lymphoma 2 associated X protein (Bax) levels in gingival
fibroblasts [69].
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Figure 1:MajorQBA cytotoxicity against normal andmalignant cells 24 hr incubation.Data from [34, 69, 71]. Cell line: GF: gingival fibroblast;
EK: epidermal keratinocyte; MDA-MB231: breast; HCT116: bowel; OVCAR-3: ovarian; A431: SCC; Du-145: prostate; MCF-7: breast; LNCaP:
prostate.
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Figure 2: Minor QBA cytotoxicity against normal and malignant cells 72 hr incubation. Data from [32, 35]. Cell line: LF: lung fibroblast; SF:
skin fibroblast; HL60: leukaemia; A-2780: ovarian; HeLa: cervical; A431: SCC.
As epidermal keratinocytes provide a barrier to environ-
mental toxins, they contain antioxidant levels 200% higher
than those found in fibroblasts [70]. Oxidative stress has been
suggested as a key mechanism of sanguinarine action [71],
with the greater resistance to sanguinarine cytotoxicity of
epidermal keratinocytes (IC50 10 𝜇M) compared to fibroblasts
(IC50 1.2 𝜇M) possibly due to the increased antioxidant
reserve of these cells.
ZnCl2 also has well described cytotoxicity against L929
murine fibroblast cultures, having an IC50 of 0.928𝜇M,
classifying it as a highly cytotoxicmetal salt [36]. At high con-
centrations of 80𝜇g/mL or 0.6mM,ZnCl2 exposure results in
40% HLE B-3 human epithelial cell death by either apoptosis
or necrosis [72]. Thus, current in vitro evidence suggests the
twomain ingredients of black salve, bloodroot and ZnCl2, are
indiscriminate in their cytotoxic action at concentrations that
may be present in black salve preparations.
Black salves contain additional botanical ingredients that
may also have normal cell cytotoxicity (Table 1). Chaparral
(Larrea tridentata) leaves contain multiple phytochemicals
including nordihydroguaiaretic acid (NDGA), a polyphenol
lignin that constitutes 5–10% of leaf dry weight [73]. HaCaT
immortalized human keratinocytes exposed to 150 𝜇M of
NDGAundergo apoptosis indicated by a complete disappear-
ance of poly (ADP-ribose) polymerase (PARP) [37]. Some
black salves contain 17% NDGA by weight [28]. Graviola
(Annona muricata) leaves are a rich source of acetogenin
(AGEs) long chain fatty acids. Over 100 AGEs have so far
been identified in the plant,manywith promising antitumour
activity [74]. Cytotoxicity has been reported with an A.
muricata extract against WRL-68 normal hepatic cells, with
an IC50 of 52.4𝜇g/mL [75]. Oleander (Nerium oleander)
may also be a constituent and contains antitumour cardiac
glycosides [76] such as oleandrin [77]. Oleandrin at concen-
trations of 0.6 𝜇g/mL (1.04 𝜇M)did not have a cytotoxic effect
on isolated human peripheral blood mononuclear cells or
neutrophils [78] but normal cell cytotoxicity has not been
assessed at higher concentrations.
As a natural product, the alkaloid composition of S. cana-
densis shows natural variation, being influenced by a number
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Table 1: Black salve constituent normal cell cytotoxicity.
Compound Cell type IC50 (𝜇M) Ref
Sanguinarine
Skin fibroblasts KF-II 1 [32]
Gingival fibroblasts 1.2 [33]
Epidermal keratinocytes 10 [34]
Chelerythrine Skin fibroblasts KF-II 1.5 [32]
Gingival fibroblasts 4.7 [33]
Sanguilutine Lung fibroblasts 1.2 [35]
Chelilutine Lung fibroblasts 1.7 [35]
Sanguirubine Skin fibroblasts KF-II 0.53 [32]
Chelirubine Skin fibroblast KF-II 0.5 [32]
Zinc chloride Murine fibroblast 0.93 [36]
NDGA HaCaT keratinocytes 150 [37]
of environmental and genetic factors [79, 80]. Bloodroot rhi-
zomes have been shown to have an up to fifteenfold variation
in sanguinarine concentration [81]. When natural products
are incorporated into therapeutic agents, it is often difficult
to control the concentration and stability of the active ingre-
dients to which patients are exposed. Even if sanguinarine
has a narrow window of preferential tumour cell cytotoxicity,
with the IC50 of A431 epidermoid carcinoma cells being
0.7 𝜇g/mL and normal human epidermal keratinocytes being
3.7 𝜇g/mL [82], small variations in black salve sanguinarine
concentration could result in normal cell cytotoxicity. Sur-
prisingly the chemical analysis of black salve has only been
reported once in the literature, this being froma single sample
with no quantitative analysis performed [47]. Currently the
black salve constituent concentration range patients may be
exposed to is unknown.
With a number of black salve constituents possessing in
vitro normal cell cytotoxicity at low concentrations, health
claims regarding black salve tumour specificity appear false.
Normal cell cytotoxicity is usually assessed with single agent
or single botanical source in vitro assays. Complex herbal
formulations such as black salve present a challenge for
assessing their cytotoxic potential. Different compounds and
botanical extracts may have antagonistic or synergistic effects
of relevance to black salve therapeutic efficacy and toxicity.
3.1. In Vivo Evidence of Nonselectivity: Histology. Studies that
have examined the histopathology of skin following the app-
lication of black salve are also counter to claims of a discrim-
inating destructive action. Treated areas typically develop an
eschar of dead tissue that sloughs off approximately ten days
after salve application, leaving an ulcer [42]. Histologically
these ulcers are surrounded by necrosis, suppurative inflam-
mation, and limited residual viable tissue [44]. Moreover,
extensive tissue necrosis has been found to develop from
the epidermis to the dermis and into subcutaneous tissues
[83]. Histological examination of a detached eschar following
black salve administration showed it to contain both malig-
nant and normal tissue, contradicting the claim that black
salve only damages cancer cells [42].
Black salve may have other pathological implications
and has been shown to induce cellular and structural atypia
in tissues that can mimic malignancy [83]. In a series of
sixteen black salve treated lesions, pathologists needed to
perform immunohistochemistry on seven lesions (44%) due
to concerning histological features such as atypical spindled
cells and necrotic melanocyte containing architecture [44].
Although initially used by patients to treat skin lesions,
black salve can result in collateral clinical and histological
pseudomalignancies that pose diagnostic challenges.
3.2. In Vivo Evidence of Nonselectivity: Mohs Paste. In 1941,
Mohs and Guyer, while investigating the reaction of cancer-
ous and normal tissues to various irritants, observed that
a 20% solution of ZnCl2 chemically killed both benign and
malignant tissues while maintaining their microscopic struc-
ture [84]. Mohs spent four years developing and testing a
fixative paste that would histologically preserve human tissue
in a controlled manner. The paste functions like a reservoir
that slowly releases ZnCl2, the depth of tissue death and
fixation determined by the thickness, and surface area of paste
application [85].
With standard skin cancer surgery, 1-2% of surgical mar-
gins are histologically examined [86]. Mohs believed histo-
logical examination of the entire margin for tumour involve-
ment would improve skin cancer cure rates. The Mohs fixed
tissue technique involves tumour site fixation with Mohs
paste. Horizontal tissue sections are sequentially removed
and histologically examined with tumour margin involve-
ment being mapped; further tissue fixative is then applied
to persisting tumour until clear margins are obtained [87].
Using the fixed tissue method, Mohs 5-year cure rate, despite
a complicated case load where 20% of patients had recurrent
disease, was 99.3% for BCC based on 7,257 cases and 94.4%
for SCC based on 2,551 cases [88].
In contrast to black salves, where ZnCl2 concentration
has not been reported, Mohs fixative paste contains 45.2%
ZnCl2 by weight [84]. Small millimetre-scale changes in
paste thickness resulted in significant changes to the depth of
fixative penetration. To perform its function,Mohs paste fixes
and kills both benign and healthy tissue. The Mohs histology
slides of 1000s of patients from the past 75 years attest to
the indiscriminate toxicity of salves containing ZnCl2 and S.
canadensis.
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Table 2: Black salve skin cancer treatment clinical outcomes.
Cancer type Number of cases Outcome Ref
Melanoma 2 2 metastatic melanomas [38, 39]
SCC 3
1 metastatic SCC [40]
1 persisting SCC [41]
1 recurrence-free histologically [42]
BCC 14
1 metastatic BCC [43]
4 persisting BCC [44–46]
3 recurrence-free clinically [47–49]
6 recurrence-free histologically [42–44]
The experience of Mohs fixed tissue technique highlights
the potentially destructive power of escharotics. Mohs also
used his paste to treat gangrene. Applying a thin 2mm
layer to a gangrenous toe for 24 hours fixed the entire toe,
facilitating amputation [89]. In this 24-hour timeframe, tissue
destruction to a depth of 2 cm can occur [90], with the
rapid penetration rate for some normal tissues like cartilage
rendering them more susceptible to excessive tissue damage
[87].
Black salve has been portrayed as a therapy that selectively
destroys tumour cells, enabling it to cure 98–100% of skin
cancers with minimal scarring [57]. The indiscriminate in
vitro cytotoxicity of both S. canadensis alkaloids and zinc
chloride, the histological evidence showing normal tissue
necrosis in patients that have used black salve, and the adverse
event case studies in the medical literature all suggest black
salve lacks tumour specificity.
4. Is Black Salve Effective at Curing
Skin Cancer?
The literature contains 14 journal articles and abstracts that
report the use of black salves derived from S. canadensis
in 19 pathology confirmed skin cancers from 15 individuals
(Table 2). While case studies cannot determine efficacy or
assess toxicity rates, they can provide information about
potential toxicities and characterise treatment failures. Black
salves have been used to treat melanoma, squamous cell
carcinoma (SCC), and basal cell carcinoma (BCC) with
varying results as detailed below.
A number of Internet sites suggest that black salve can
be used to treat melanoma effectively [91, 92]. The scientific
literature does not support this claim.Of the two documented
patients that have used black salve to treat melanoma, both
developed metastatic disease [38, 39]. One of these patients
had a superficial 0.6mmBreslow thickness melanoma on her
calf with an anticipated 12-year survival rate with conven-
tional surgical management of 92.2% [93].
Nonmelanoma skin cancers have also been treated with
black salve. Squamoproliferative lesions include two SCCs
[40, 42] and a keratoacanthoma (KA) [41]. While one patient
showed no evidence of persisting SCC on partial biopsy of
their black salve treatment site, the other two patients showed
persisting malignancy. One presented with a 10 cm diameter
scalp SCC with perineural invasion and regional lymph node
metastases despite black salve application [40].
Basal cell carcinomas (BCCs) have had mixed results
when treated by black salve. A total of nine out of 14
BCCs (64%) appeared to be treated successfully. However,
only two of these cases had the entire salve treatment area
excised and examined histologically [42, 43], with five other
cases having a posttreatment biopsy that did not show BCC
persistence [44, 48]. Two additional cases were clinically free
of recurrence at 6months’ [47] and 12months’ follow-up [49],
too short a timeframe to determine if the treatment had been
curative.
Black salve BCC treatment failures resulted in 8-stage and
10-stage Mohs surgery being required to completely remove
a scalp and separate nose BCC in one patient [45]. Another
patient had a nose BCC recur after apparent resolution with
black salve. The tumour infiltrated the maxilla requiring
partial maxillectomy; the BCC subsequently metastasized to
regional lymph nodes with the patient dying of metastatic
BCC despite radical neck lymphadenectomy with adjuvant
radiotherapy [43].
Conventional surgical skin cancer management has been
assessed in multiple clinical trials, individually involving
thousands of patients. These have shown primary BCC cure
rates of 95.2% for clinical margin surgery [94] and 99.5%
for Mohs Micrographic Surgery [95]. Primary SCC has a 5-
year recurrence free rate of 94.6% with standard excision
[96] and 97.4% with MMS [97]. In melanoma the prognosis
varies depending on tumour thickness ranging from a 92%
10-year survival for lesions <1mm thick to a 50% 10-year
survival for lesions >4mm thick [98].Themajority of lesions
are thin melanomas [99]. Despite the likely publication bias
favouring the reporting of negative outcomes following black
salve use in the medical literature, claims that black salve has
superior or equivalent efficacy to surgery are currently not
substantiated.
Clinicians are trained to assess the risk that skin lesions
pose using variables such as histological subtype, lesion
location, diameter, and thickness [100]. Compared to surgical
excisions which have a 96% cure rate for BCC [101], the
topical cream Imiquimod has a clearance rate for superficial
and nodular BCC of 85% and 81%, respectively, [102] but only
56% for infiltrating or aggressive BCC subtypes [103]. For this
reason the standard of care for aggressive BCC subtypes is
surgical excision [104].
Currently the pharmacokinetics of black salve are not
known. While surface eschar formation may be reassuring
to patients, the depth of its cytotoxic effect has not been
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determined. Malignancy may persist under black salve scar
tissue and extend subcutaneously before becoming clinically
apparent [45]. Without an understanding of skin cancer
biology and behaviour, unsuitable lesions can be selected by
patients for black salve topical treatment, placing them at
increased risk of recurrence and metastatic disease.
5. Does Black Salve Cause Less Scarring
Than Surgery?
Surgery by primary closure results in healing where wound
edges are in apposition. Black salve leaves an open wound
that heals by secondary intention. Secondary intention heal-
ing begins with basal wound granulation and wound edge
contraction followed by subsequent reepithelialization [105].
ZnCl2 escharotics have been used to treat venous ulcers [106]
and osteomyelitis [107]. In Mohs surgery the fixative paste
provides an infection resistant platform for wound healing
with rapid epithelialization where defects of 8 cm diameter
have healed completely in six weeks [108].
The cosmetic result for healing by secondary intention
depends on the site and size of the defect.With facial wounds,
concave areas of the nose, eye, ear, and temple (NEET
regions) have cosmetic outcomes often superior to transpo-
sition flaps and grafts [109, 110]. Wounds on convex areas
such as the nasal tip and nasal ala however heal with poor
cosmetic results [111]. Smaller wounds <2 cm in diameter
predictably heal better than larger wounds, having greater
tissue contraction, resulting in less scar tissue deposition
[112]. Facial defects involvingmore than one cosmetic subunit
usually have poor cosmetic results with second intention
healing [111]. The cosmetic outcome for patients using black
salve will depend to some extent on the site, size, and number
of cosmetic subunits to which it has been applied. Black salve
ulcers are surrounded by inflamed and necrotic tissue [44]
from which regeneration tries to occur, the ulcer potentially
taking up to 2 years to heal [57].
It is difficult from the available literature to assess defini-
tively the cosmetic outcomes for patients that have used
black salve. A standardized measure for cosmesis is not used
by authors, with some papers not recording the cosmetic
outcome or failing to identify the number of sites where black
salve was applied. Within these limitations there are reports
relating to a total of 36 patients that have treated 43 skin
lesions with black salve. These reports include 19 confirmed
malignancies and 24 lesions of either benign histology or
where histology was not taken [113, 114]. Of these 43 lesions,
four lack a comment on cosmesis, five had a persisting
tumour, and nine were in the ulcerative stage. The ulcerative
stage follows sloughing of the black salve eschar; as an open
wound it prevents an assessment of final cosmesis to bemade.
Of the 25 lesions that have some cosmetic outcome
information documented (Table 3), the cosmetic outcome for
two lesions (8% of black salve assessable cases) is reported
as fair to good in the literature. In one of these cases
where a nasal tip BCC was treated with black salve for
eight consecutive days the patient was left with a depressed,
irregular scar which the dermatologist authors described as
a fair cosmetic outcome [48]. In the other case, where a R
Table 3: Black salve cosmetic results.
Cosmetic outcome Number of cases Ref
Fair to good 2 [47, 50]
Scarring 13 [42, 51, 52]
Keloid scarring 2 [43, 44]
Concerning pigmentation
changes 3 [44]
Deformity 5 [43, 46, 53–55]
nasal sidewall BCC was treated for 6 days with alternating
black and yellow salves at a six-month review the patient had
a good cosmetic outcome [47].
In thirteen cases (52%) scarring was noted after black
salve application without grading cosmesis. These include
a large neck eschar that required management with oral
and topical corticosteroids [51], a biopsy proven compound
naevus on a 35-year-old woman’s thigh that developed into a
5 cm granulomatous plaque [52] and a 29-year-old man who
developed cheek scarring that required three scar revision
surgeries [42]. Two treatment areas (8%) developed keloid
scarring [44] with one requiring cosmetic surgery [43], and
an additional three treatment areas (12%) had pigmentation
changes necessitating histological assessment [44].
Themost graphic cosmetic adverse events occurred in five
individuals (20%) that suffered deformity as a consequence
of black salve use. All five cases involved the nose with two
patients losing an ala unit [43, 46] and another suffering
a through-and-through nasal alar defect requiring a hinge
flap repair [53]. The most extensive destruction however
occurred with two female patients having the majority of
their nose destroyed by black salve [54, 55].These individuals
subsequently required a number of reconstructive surgical
procedures in an attempt to repair the escharotic damage they
sustained.
Although selection bias will favour the reporting of
adverse events in relation to black salve, it is notable that, of
25 cases available for cosmetic assessment in the literature,
only 8% report a good or fair cosmetic outcome.The number
of case studies reporting scarring, keloid formation, and
disfiguring deformity suggests black salve has the potential
to cause significant cosmetic harm. In contrast, of 174 patients
undergoing standard excision, 87% rated their cosmetic result
as good [115], while 93%of 228 patients reported a satisfactory
or good rating followingMohs surgery [116].While portrayed
as a cosmetically superior treatment to surgery, black salve’s
mechanism of action and suspected indiscriminate toxicity
suggest this is not the case. Black salve has not spared
a number of patients from requiring surgery to correct
cosmetic damage or treat persisting malignancy.
6. Discussion
An increasing number of patients are turning to the Internet
to provide them with information about healthcare and
treatment options [117]. As an unregulated space, there is
the potential for inaccurate or misleading claims to result in
choices leading to harmful health outcomes [118].
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Mohs was aware of the toxicity of black salve type esc-
harotics, where an extra millimetre of salve thickness could
result in significant tissue destruction. For this reason he
patented his paste [119] to prevent untrained individuals from
using it as a blind chemosurgical technique [120]. Some have
suggested that Mohs paste, in addition to facilitating the
histological excision of skin cancers, may possess immune
enhancing effects [121]. Evidence of improved five-year sur-
vival rates in Mohs treated melanoma patients compared to
a historical standard excision control cohort furthers these
claims [122]. This study however did not determine whether
salve pharmaceutical effects or the process of microscopic
tumour removal was responsible; it also relied on bias prone
historical control data. Claims of an immune adjuvant Mohs
paste effect are currently therefore unsubstantiated. The
benefit of Mohs paste lies not in its action as a cancer killing
therapy but rather in its ability to fix tissue, allowing a cancer
to be microscopically mapped and removed. The equivalent
cure rates of the Mohs fixed tissue technique utilizing Mohs
paste, and the subsequently developed Mohs fresh tissue
technique without Mohs paste, attest to this fact [123]. Mohs
paste has a very limited role in contemporary clinical practice
being reserved for skin tumours that invade bone [124],
neoplastic pelvic bleeding [125], and palliative local cancer
control [126].
A number of bold claims have beenmade regarding black
salve. Currently the evidence does not exist to confirm or
dismiss the claim that black salve has a better cure rate than
surgery or that it results in a better cosmetic outcome than
surgery for patients.This would require a randomized clinical
trial, which has not occurred in the 150-year history of black
salve use. Substituting highly effective conventional therapies
with an unproven alternative such as black salve should not
occur outside the framework of a clinical trial.
Regulators have been trying to protect consumers from
black salve by policing the claims vendors post on their
websites [127] and by making it illegal to import or sell black
salve [128]. A number of loopholes however exist in the
regulatory framework. Vendorsmay relocate their operations
to countries with reduced regulatory controls [57], black salve
ingredients can be legally imported from which patients can
manufacture their own salve [129], and black salve veterinary
products can be imported and used by humans [130]. While
regulation is a valuable pillar in harm prevention, it is failing
to limit escharotic salve use to treat skin cancer.
Skin cancer is the most common malignancy in the
western world. The annual cost to the US health system from
2007 to 2011 was $8.1 billion, with skin cancer expenditure
growing 126.2% over the 5-year period compared to a 25.1%
cost increase for all other cancers [131]. In 2007 $34 billion
was spent on CAM in the US [6]. With growing demand
and an absence of clinical evidence assessing the benefits
and risks of black salve, patients will continue experimenting.
Observational studies and clinical trials offer a mechanism
for assessing the efficacy of black salve; they may also
facilitate harm minimisation by discouraging black salve use
for melanomas, high risk nonmelanoma skin cancers, and
obviously benign lesions.
7. Conclusion
Black salve is not a natural therapy. It contains significant
concentrations of synthetic chemicals. Black salve does not
appear to possess tumour specificity with in vitro and in
vivo evidence indicating normal cell toxicity. Black salve does
appear to cure some skin cancers, although the cure rate for
this therapy is currently unknown. The use of black salve
should be restricted to clinical research in low risk malig-
nancies located at low risk sites until a better understanding
of its efficacy and toxicity is developed. Where a therapy
capable of harm is already being used by patients, it is
ethically irresponsible not to study and analyse its effects.
Although cautionary tales are valuable, black salve research
needs to move beyond the case study and into the carefully
designed clinical trial arena. Only then can patients be
properly informed of its true benefits and hazards.
Competing Interests
The authors declare that they have no conflict of interests.
References
[1] C. Zollman and A. Vickers, “ABC of complementary medicine:
what is complementary medicine?” British Medical Journal, vol.
319, no. 7211, pp. 693–696, 1999.
[2] H. A. Tindle, R. B. Davis, R. S. Phillips, and D. M. Eisenberg,
“Trends in use of complementary and alternative medicine
by US adults: 1997–2002,” Alternative Therapies in Health and
Medicine, vol. 11, no. 1, pp. 42–49, 2005.
[3] B. Bu¨cker, M. Groenewold, Y. Schoefer, and T. Scha¨fer, “The
use of complementary alternative medicine (CAM) in 1 001
German adults: results of a population-based telephone survey,”
Gesundheitswesen (Bundesverband der Arzte des Offentlichen
Gesundheitsdienstes (Germany)), vol. 70, no. 8-9, pp. e29–e36,
2008.
[4] C. C. L. Xue, A. L. Zhang, V. Lin, C. Da Costa, and D. F. Story,
“Complementary and alternative medicine use in Australia: a
national population-based survey,” Journal of Alternative and
Complementary Medicine, vol. 13, no. 6, pp. 643–650, 2007.
[5] P. M. Barnes, E. Powell-Griner, K. McFann, and R. L. Nahin,
“Complementary and alternative medicine use among adults:
United States, 2002,” Advance Data, no. 343, pp. 1–19, 2002.
[6] P. M. Barnes, B. Bloom, and R. L. Nahin, “Complementary and
alternative medicine use among adults and children: United
States, 2007,” National Health Statistics Reports, no. 12, pp. 1–23,
2008.
[7] N. Smith, D. B. Shin, J. A. Brauer, J. Mao, and J. M. Gelfand,
“Use of complementary and alternative medicine among adults
with skin disease: results from a national survey,” Journal of the
American Academy of Dermatology, vol. 60, no. 3, pp. 419–425,
2009.
[8] S. E. Baron, R. G. Goodwin, N. Nicolau, S. Blackford, and V.
Goulden, “Use of complementary medicine among outpatients
with dermatologic conditions within Yorkshire and South
Wales, United Kingdom,” Journal of the American Academy of
Dermatology, vol. 52, no. 4, pp. 589–594, 2005.
[9] J. D. Berman and S. E. Straus, “Implementing a research agenda
for complementary and alternativemedicine,”Annual Review of
Medicine, vol. 55, no. 1, pp. 239–254, 2004.
8 Evidence-Based Complementary and Alternative Medicine
[10] M. Angell and J. P. Kassirer, “Alternative medicine—the risks
of untested and unregulated remedies,” New England Journal of
Medicine, vol. 339, no. 12, pp. 839–841, 1998.
[11] D. J. Newman and G. M. Cragg, “Natural products as sources
of new drugs over the 30 years from 1981 to 2010,” Journal of
Natural Products, vol. 75, no. 3, pp. 311–335, 2012.
[12] J.-Y. Ortholand and A. Ganesan, “Natural products and com-
binatorial chemistry: back to the future,” Current Opinion in
Chemical Biology, vol. 8, no. 3, pp. 271–280, 2004.
[13] S. Bent, “Herbal medicine in the United States: review of
efficacy, safety, and regulation—Grand Rounds at University of
California, San Francisco Medical Center,” Journal of General
Internal Medicine, vol. 23, no. 6, pp. 854–859, 2008.
[14] X. Zhang,Regulatory Situation of HerbalMedicines aWorldwide
Review, vol. 26, World Health Organization, Geneva, Switzer-
land, 1998.
[15] S. Board, “Botanical medicines—the need for new regulations,”
The New England Journal of Medicine, vol. 347, no. 25, 2002.
[16] A. D. M. C. Shaw, C. H. Moore, and M. Henry, “Editorial,”
Western Lancet, A Monthly Journal of Practical Medicine and
Surgery, vol. 18, pp. 541–542, 1857.
[17] A. Croaker, G. King, J. Pyne, S. Anoopkumar-Dukie, and L. Liu,
“Sanguinaria canadensis: traditional medicine, phytochemical
composition, biological activities and current uses,” Interna-
tional Journal of Molecular Sciences, vol. 17, no. 9, article 1414,
2016.
[18] J. W. Fell, “DR. Fell’s treatment of cancer,” The Lancet, vol. 70,
no. 1785, p. 507, 1857.
[19] D. M. Elston, “Escharotic agents, Fred Mohs, and Harry
Hoxsey,” Journal of the American Academy of Dermatology, vol.
53, no. 3, pp. 523–525, 2005.
[20] Natures Scalpel, http://www.blacksalve.biz/black salve.php.
[21] F. L. Bishop, L. Yardley, and G. T. Lewith, “Why do people
use different forms of complementary medicine? Multivariate
associations between treatment and illness beliefs and comple-
mentary medicine use,” Psychology & Health, vol. 21, no. 5, pp.
683–698, 2006.
[22] AlphaOmegaLabs, http://www.alphaomegalabs.com/store/can-
semar-black-salve.html?SID=713077897fa03d416e83f0408ebbe831.
[23] Best on Earth Black Salve, http://bestonearthproducts.com/
Black-Salve.
[24] Virxcan-X Blog, http://virxcan.org/what-is-in-virxcan-x-salve-
and-tablets.html.
[25] Herbal Plus Black Salve, http://www.lifelixir.com/Black-Salve-Tab-
lets.html.
[26] K. Schmetzer, G. Schnorrer-Kohler, andO.Medenbach, “Wulfi-
ngite, epsilon-Zn(OH)2, and simonkolleite, Zn5(OH)8Cl2.H2O,
two new minerals from Richelsdorf, Hesse, F.R.G.,” Neues
Jahrbuch fur Mineralogie, Monatshefte, no. 4, pp. 145–154, 1985.
[27] M. K. Jha, V. Kumar, and R. J. Singh, “Review of hydromet-
allurgical recovery of zinc from industrial wastes,” Resources,
Conservation and Recycling, vol. 33, no. 1, pp. 1–22, 2001.
[28] AlphaOmegaLabs, https://www.alphaomegalabs.com/product/
266-cansema-black-topical-salve-22g.
[29] T. W. Pearson, H. J. Dawson, and H. B. Lackey, “Naturally
occurring levels of dimethyl sulfoxide in selected fruits, veg-
etables, grains, and beverages,” Journal of Agricultural and Food
Chemistry, vol. 29, no. 5, pp. 1089–1091, 1981.
[30] K. Capriotti and J. A. Capriotti, “Dimethyl sulfoxide: history,
chemistry, and clinical utility in dermatology,” Journal of Clini-
cal and Aesthetic Dermatology, vol. 5, no. 9, pp. 24–26, 2012.
[31] N. A. David, “The pharmacology of dimethyl sulfoxide,”Annual
review of pharmacology, vol. 12, pp. 353–374, 1972.
[32] I. Slaninova´, Z. Slunska´, J. Sˇinkora, M. Vlkova´, and E. Ta´borska´,
“Screening of minor benzo(c.)phenanthridine alkaloids for
antiproliferative and apoptotic activities,” Pharmaceutical Biol-
ogy, vol. 45, no. 2, pp. 131–139, 2007.
[33] J. Mal´ıkova´, A. Zdarˇilova´, A. Hlobilkova´, and J. Ulrichova´,
“The effect of chelerythrine on cell growth, apoptosis, and cell
cycle in human normal and cancer cells in comparison with
sanguinarine,” Cell Biology and Toxicology, vol. 22, no. 6, pp.
439–453, 2006.
[34] N. Ahmad, S. Gupta, M. M. Husain, K. M. Heiskanen, and H.
Mukhtar, “Differential antiproliferative and apoptotic response
of sanguinarine for cancer cells versus normal cells,” Clinical
Cancer Research, vol. 6, no. 4, pp. 1524–1528, 2000.
[35] Z. Slunska´, E. Gelnarova´, J. Hammerova´, E. Ta´borska´, and
I. Slaninova´, “Effect of quaternary benzo[c]phenanthridine
alkaloids sanguilutine and chelilutine on normal and cancer
cells,” Toxicology in Vitro, vol. 24, no. 3, pp. 697–706, 2010.
[36] A. Yamamoto, R. Honma, and M. Sumita, “Cytotoxicity evalu-
ation of 43 metal salts using murine fibroblasts and osteoblastic
cells,” Journal of BiomedicalMaterials Research, vol. 39, no. 2, pp.
331–340, 1998.
[37] J. Pachernı´k, A. Hampl, K. Soucˇek et al., “Multiple biological
effects of inhibitors of arachidonic acid metabolism on human
keratinocytes,”Archives of Dermatological Research, vol. 293, no.
12, pp. 626–633, 2002.
[38] J. J. Cienki and L. Zaret, “An Internet misadventure: blood-
root salve toxicity,” Journal of Alternative and Complementary
Medicine, vol. 16, no. 10, pp. 1125–1127, 2010.
[39] G. Sivyer and C. Rosendahl, “Application of black salve to
a thin melanoma that subsequently progressed to metastatic
melanoma: a case study,” Dermatology Practical & Conceptual,
vol. 4, no. 3, pp. 77–80, 2014.
[40] L. Ma, J. W. Dharamsi, and T. Vandergriff, “Black salve as self-
treatment for cutaneous squamous cell carcinoma,” Dermatitis,
vol. 23, no. 5, pp. 239–240, 2012.
[41] J. M. Tan, P. Peters, N. Ong, B. Shepherd, and H. P. Soyer,
“Histopathological features after topical black salve application,”
Australasian Journal of Dermatology, vol. 56, pp. 75–76, 2015.
[42] C. W. Brown, G. D. Goldstein, and C. S. Birkby, “Auto-
Mohs.com,” Dermatologic Surgery, vol. 27, no. 11, pp. 975–978,
2001.
[43] S. McDaniel and G. D. Goldman, “Consequences of using
escharotic agents as primary treatment for nonmelanoma skin
cancer,” Archives of Dermatology, vol. 138, no. 12, pp. 1593–1596,
2002.
[44] T. N. Leecy, T. W. Beer, N. T. Harvey et al., “Histopathological
features associated with application of black salve to cutaneous
lesions: a series of 16 cases and review of the literature,”
Pathology, vol. 45, no. 7, pp. 670–674, 2013.
[45] N. Jellinek and M. E. Maloney, “Escharotic and other botanical
agents for the treatment of skin cancer: a review,” Journal of the
American Academy of Dermatology, vol. 53, no. 3, pp. 487–495,
2005.
[46] K. L. Eastman, L. V. Mcfarland, and G. J. Raugi, “A review
of topical corrosive black salve,” Journal of Alternative and
Complementary Medicine, vol. 20, no. 4, pp. 284–289, 2014.
[47] S. S. Osswald, D. M. Elston, M. F. Farley, J. G. Alberti, S. C.
Cordero, and V. F. Kalasinsky, “Self-treatment of a basal cell
carcinomawith ‘black and yellow salve’,” Journal of the American
Academy of Dermatology, vol. 53, no. 3, pp. 509–511, 2005.
Evidence-Based Complementary and Alternative Medicine 9
[48] A. G. Affleck and S. Varma, “A case of do-it-yourself Mohs’
surgery using bloodroot obtained from the internet,” British
Journal of Dermatology, vol. 157, no. 5, pp. 1078–1079, 2007.
[49] F. Saltzberg, G. Barron, and N. Fenske, “Deforming self-
treatment with herbal ‘black salve’,” Dermatologic Surgery, vol.
35, no. 7, pp. 1152–1154, 2009.
[50] A. G. Affleck and S. Varma, “A case of do-it-yourself Mohs’
surgery using bloodroot obtained from the internet [23],”
British Journal of Dermatology, vol. 157, no. 5, pp. 1078–1079,
2007.
[51] M. J. Schlichte, C. P. Downing, M. Ramirez-Fort, R. Gordon,
and S. Tyring, “Bloodroot associated eschar,” Dermatology
Online Journal, vol. 20, no. 7, 2014.
[52] J. L. Hou and J. D. Brewer, “Black salve and bloodroot extract in
dermatologic conditions,”Cutis, vol. 95, no. 6, pp. 309–311, 2015.
[53] K. Bickle and R. G. Bennett, “Combined hinge flap full-
thickness skin graft for a through-and-through nasal defect,”
Dermatologic Surgery, vol. 34, no. 3, pp. 389–392, 2008.
[54] Disciplinary Action against Jerome Craft MD, in Florida
Medical Board Disciplinary Action against Jerome Craft MD,
https://www.casewatch.org/board/med/craft/complaint 2006
.shtml.
[55] The United States District Court for the Southern District of
Indiana, Indianapolis Division Case No. 1:03-CV-1183 LJM-
WTL, 2004.
[56] F. L. Bishop, L. Yardley, and G. T. Lewith, “A systematic review
of beliefs involved in the use of complementary and alternative
medicine,” Journal of Health Psychology, vol. 12, no. 6, pp. 851–
867, 2007.
[57] Cansema and Escharotics FAQ, http://www.altcancer.com/
faq101.htm.
[58] N. C. Ong, E. Sham, and B. M. Adams, “Use of unlicensed black
salve for cutaneous malignancy,” Medical Journal of Australia,
vol. 200, no. 6, p. 314, 2014.
[59] J. Slavı´k and L. Slavı´kova´, “Alkaloide der mohngewa¨chse
(Papaveraceae) XVII. U¨ber neue alkaloide aus Sanguinaria
canadensis L.,” Collection of Czechoslovak Chemical Communi-
cations, vol. 25, no. 6, pp. 1667–1675, 1960.
[60] M. Wink, T. Schmeller, and B. Latz-Bru¨ning, “Modes of action
of allelochemical alkaloids: interaction with neuroreceptors,
DNA, and othermolecular targets,” Journal of Chemical Ecology,
vol. 24, no. 11, pp. 1881–1937, 1998.
[61] L.-P. Bai, Z.-Z. Zhao, Z. Cai, and Z.-H. Jiang, “DNA-binding
affinities and sequence selectivity of quaternary benzophenan-
thridine alkaloids sanguinarine, chelerythrine, and nitidine,”
Bioorganic and Medicinal Chemistry, vol. 14, no. 16, pp. 5439–
5445, 2006.
[62] S. R. Chowdhury, M. M. Islam, and G. S. Kumar, “Binding of
the anticancer alkaloid sanguinarine to double stranded RNAs:
insights into the structural and energetics aspects,” Molecular
BioSystems, vol. 6, no. 7, pp. 1265–1276, 2010.
[63] P. Giri and G. S. Kumar, “Specific binding and self-structure
induction to poly(A) by the cytotoxic plant alkaloid sanguinar-
ine,” Biochimica et Biophysica Acta—General Subjects, vol. 1770,
no. 9, pp. 1419–1426, 2007.
[64] M. Hossain, A. Kabir, and G. S. Kumar, “Binding of the
anticancer alkaloid sanguinarine with tRNA𝑝ℎ𝑒: spectroscopic
and calorimetric studies,” Journal of Biomolecular Structure and
Dynamics, vol. 30, no. 2, pp. 223–234, 2012.
[65] R. Selvi B, S. K. Pradhan, J. Shandilya et al., “Sanguinarine
interacts with chromatin, modulates epigenetic modifications,
and transcription in the context of chromatin,” Chemistry &
Biology, vol. 16, no. 2, pp. 203–216, 2009.
[66] M. Lopus and D. Panda, “The benzophenanthridine alkaloid
sanguinarine perturbsmicrotubule assembly dynamics through
tubulin binding: a possible mechanism for its antiproliferative
activity,” FEBS Journal, vol. 273, no. 10, pp. 2139–2150, 2006.
[67] A. Burgeiro, A. C. Bento, C. Gajate, P. J. Oliveira, and F.
Mollinedo, “Rapid human melanoma cell death induced by
sanguinarine through oxidative stress,” European Journal of
Pharmacology, vol. 705, no. 1–3, pp. 109–118, 2013.
[68] E. Debiton, J.-C. Madelmont, J. Legault, and C. Barthomeuf,
“Sanguinarine-induced apoptosis is associatedwith an early and
severe cellular glutathione depletion,” Cancer Chemotherapy
and Pharmacology, vol. 51, no. 6, pp. 474–482, 2003.
[69] J. Malikova, A. Zdarilova, and A. Hlobilkova, “Effects of
sanguinarine and chelerythrine on the cell cycle and apoptosis,”
Biomedical Papers of the Medical Faculty of the University
Palacky´, Olomouc, Czechoslovakia, vol. 150, no. 1, pp. 5–12, 2006.
[70] M.-T. Leccia, M.-J. Richard, F. Joanny-Crisci, and J.-C. Beani,
“UV-A1 cytotoxicity and antioxidant defence in keratinocytes
and fibroblasts,” European Journal of Dermatology, vol. 8, no. 7,
pp. 478–482, 1998.
[71] S. S. Matkar, L. A. Wrischnik, and U. Hellmann-Blumberg,
“Production of hydrogen peroxide and redox cycling can
explain how sanguinarine and chelerythrine induce rapid apop-
tosis,”Archives of Biochemistry and Biophysics, vol. 477, no. 1, pp.
43–52, 2008.
[72] Y. Du, D. Guo, Q. Wu, D. Liu, and H. Bi, “Zinc chloride inhibits
human lens epithelial cell migration and proliferation involved
in TGF-𝛽1 and TNF-𝛼 signaling pathways in HLE B-3 cells,”
Biological Trace Element Research, vol. 159, no. 1, pp. 425–433,
2014.
[73] J.-M. Lu¨, J. Nurko, S. M.Weakley et al., “Molecular mechanisms
and clinical applications of nordihydroguaiaretic acid (NDGA)
and its derivatives: an update,”Medical Science Monitor, vol. 16,
no. 5, pp. Ra93–Ra100, 2010.
[74] N. H. Oberlies, C.-J. Chang, and J. L. McLaughlin, “Structure-
activity relationships of diverse annonaceous acetogenins
against multidrug resistant human mammary adenocarcinoma
(MCF-7/Adr) cells,” Journal of Medicinal Chemistry, vol. 40, no.
13, pp. 2102–2106, 1997.
[75] V. Cijo George, D. R. Naveen Kumar, V. Rajkumar, P. K.
Suresh, and R. Ashok Kumar, “Quantitative assessment of the
relative antineoplastic potential of the n-butanolic leaf extract
of Annona Muricata Linn. in normal and immortalized human
cell lines,”Asian Pacific Journal of Cancer Prevention, vol. 13, no.
2, pp. 699–704, 2012.
[76] S. K. Manna, N. K. Sah, R. A. Newman, A. Cisneros, and
B. B. Aggarwal, “Oleandrin suppresses activation of nuclear
transcription factor-𝜅B, activator protein-1, and c-Jun NH2-
terminal kinase,”Cancer Research, vol. 60, no. 14, pp. 3838–3847,
2000.
[77] M. S. Karawya, S. I. Balbaa, and S. E. Khayyal, “Estimation of
cardenolides in Nerium oleander,” Planta Medica, vol. 23, no. 1,
pp. 70–73, 1973.
[78] Y. Sreenivasan, A. Sarkar, and S. K. Manna, “Oleandrin sup-
presses activation of nuclear transcription factor-𝜅B and acti-
vator protein-1 and potentiates apoptosis induced by ceramide,”
Biochemical Pharmacology, vol. 66, no. 11, pp. 2223–2239, 2003.
[79] A. K. Salmore andM.D.Hunter, “Environmental and genotypic
influences on isoquinoline alkaloid content in Sanguinaria
10 Evidence-Based Complementary and Alternative Medicine
canadensis,” Journal of Chemical Ecology, vol. 27, no. 9, pp. 1729–
1747, 2001.
[80] A. K. Salmore and M. D. Hunter, “Elevational trends in
defense chemistry, vegetation, and reproduction in Sanguinaria
canadensis,” Journal of Chemical Ecology, vol. 27, no. 9, pp. 1713–
1727, 2001.
[81] B. C. Bennett, C. R. Bell, and R. T. Boulware, “Geographic vari-
ation in alkaloid content of Sanguinaria canadensis (Papaver-
aceae),” Rhodora, vol. 92, pp. 57–69, 1990.
[82] I. Slaninova´, K. Peˇncˇ´ıkova´, J. Urbanova´, J. Slanina, and E.
Ta´borska´, “Antitumour activities of sanguinarine and related
alkaloids,” Phytochemistry Reviews, vol. 13, no. 1, pp. 51–68, 2014.
[83] A. M. Moran and K. F. Helm, “Histopathologic findings and
diagnostic difficulties posed with use of escharotic agents for
treatment of skin lesions: a case report and review of the
literature,” Journal of Cutaneous Pathology, vol. 35, no. 4, pp.
404–406, 2008.
[84] F. E. Mohs and M. F. Guyer, “Pre-excisional fixation of tissues
in the treatment of cancer in rats,” Cancer Research, vol. 1, no. 1,
pp. 49–51, 1941.
[85] F. E. Mohs, “Chemosurgery: a microscopically controlled
method of cancer excision,” Archives of Surgery, vol. 42, no. 2,
pp. 279–295, 1941.
[86] A. Kimyai-Asadi, L. H. Goldberg, and M. H. Jih, “Accuracy
of serial transverse cross-sections in detecting residual basal
cell carcinoma at the surgical margins of an elliptical excision
specimen,” Journal of the American Academy of Dermatology,
vol. 53, no. 3, pp. 468–473, 2005.
[87] F. E. Mohs and R. Caruso, “Chemosurgery and skin cancer,”
AORN journal, vol. 13, no. 2, pp. 89–97, 1971.
[88] F. E. Mohs, “Chemosurgery for the microscopically controlled
excision of cutaneous cancer,”Head and Neck Surgery, vol. 1, no.
2, pp. 150–166, 1978.
[89] F. E. Mohs, Chemosurgery in Cancer, Gangrene and Infections,
Featuring a New Method for the Microscopically Controlled
Excision of Cancer, Thomas, Springfield, Ill, USA, 1956.
[90] F. E. Mohs, “Chemosurgical amputation for gangrene,” Surgery,
vol. 57, no. 2, pp. 247–253, 1965.
[91] Cancer Compass Website, http://cancercompassalternateroute
.com/therapies/black-salve/.
[92] DoctorsAreDangerous, http://www.doctorsaredangerous.com/
articles/skincancer.htm.
[93] A.Maurichi, R.Miceli, T. Camerini et al., “Prediction of survival
in patients with thinmelanoma: results from amulti-institution
study,” Journal of Clinical Oncology, vol. 32, no. 23, pp. 2479–
2485, 2014.
[94] M. K. Silverman, A. W. Kopf, R. S. Bart, C. M. Grin, and M. S.
Levenstein, “Recurrence rates of treated basal cell carcinomas.
Part 3: surgical excision,” Journal of Dermatologic Surgery and
Oncology, vol. 18, no. 6, pp. 471–476, 1992.
[95] T. Wetzig, M. Woitek, K. Eichhorn, J. C. Simon, and U. Paasch,
“Surgical excision of basal cell carcinomawith complete margin
control: outcome at 5-year follow-up,” Dermatology, vol. 220,
no. 4, pp. 363–369, 2010.
[96] L. Lansbury, F. Bath-Hextall, W. Perkins, W. Stanton, and J.
Leonardi-Bee, “Interventions for non-metastatic squamous cell
carcinoma of the skin: systematic review and pooled analysis of
observational studies,”BMJ (Online), vol. 347, article f6153, 2013.
[97] I. Leibovitch, S. C. Huilgol, D. Selva, D. Hill, S. Richards, and R.
Paver, “Cutaneous squamous cell carcinoma treated with Mohs
micrographic surgery in Australia I. Experience over 10 years,”
Journal of the American Academy of Dermatology, vol. 53, no. 2,
pp. 253–260, 2005.
[98] C. M. Balch, J. E. Gershenwald, S.-J. Soong et al., “Final version
of 2009 AJCC melanoma staging and classification,” Journal of
Clinical Oncology, vol. 27, no. 36, pp. 6199–6206, 2009.
[99] D. C. Whiteman, P. D. Baade, and C. M. Olsen, “More people
die from thinmelanomas (≤ 1mm) than from thickmelanomas
(> 4mm) in Queensland, Australia,”The Journal of Investigative
Dermatology, vol. 135, no. 4, pp. 1190–1193, 2015.
[100] J.-C. Martinez and C. C. Otley, “Themanagement of melanoma
and nonmelanoma skin cancer: a review for the primary care
physician,” Mayo Clinic Proceedings, vol. 76, no. 12, pp. 1253–
1265, 2001.
[101] K.Mosterd, G. A. Krekels, F. H. Nieman et al., “Surgical excision
versus Mohs’ micrographic surgery for primary and recurrent
basal-cell carcinoma of the face: a prospective randomised
controlled trial with 5-years’ follow-up,” The Lancet Oncology,
vol. 9, no. 12, pp. 1149–1156, 2008.
[102] F. Bath-Hextall, M. Ozolins, S. J. Armstrong et al., “Surgical
excision versus imiquimod 5% cream for nodular and superfi-
cial basal-cell carcinoma (SINS): a multicentre, non-inferiority,
randomised controlled trial,”The Lancet Oncology, vol. 15, no. 1,
pp. 96–105, 2014.
[103] W. E. Love, J. D. Bernhard, and J. S. Bordeaux, “Topical
imiquimod or fluorouracil therapy for basal and squamous cell
carcinoma: a systematic review,” Archives of Dermatology, vol.
145, no. 12, pp. 1431–1438, 2009.
[104] N. R. Telfer, G. B. Colver, and C. A. Morton, “Guidelines for
the management of basal cell carcinoma,” British Journal of
Dermatology, vol. 159, no. 1, pp. 35–48, 2008.
[105] A. E. Rivera and J.M. Spencer, “Clinical aspects of full-thickness
wound healing,”Clinics in Dermatology, vol. 25, no. 1, pp. 39–48,
2007.
[106] V. Falanga andM. Iriondo, “Zinc chloride paste for the debride-
ment of chronic leg ulcers,” Journal of Dermatologic Surgery and
Oncology, vol. 16, no. 7, pp. 658–661, 1990.
[107] R. G. Bennett and M. P. Goldman, “Chemosurgical debride-
ment of osteomyelitic bone by zinc chloride fixative,” Journal of
Dermatologic Surgery and Oncology, vol. 13, no. 7, pp. 771–775,
1987.
[108] J. B. Moles and B. C. Ghosh, “Chemosurgery for basal cell
carcinoma,” The Journal of the American Medical Association,
vol. 210, no. 9, pp. 1759–1761, 1969.
[109] J. A. Zitelli, “Secondary intention healing: an alternative to
surgical repair,” Clinics in Dermatology, vol. 2, no. 3, pp. 92–106,
1984.
[110] G. Bernstein, “Healing by secondary intention,” Dermatologic
Clinics, vol. 7, no. 4, pp. 645–660, 1989.
[111] F. F. Becker, “Secondary healing after Mohs chemosurgery,”
Plastic and Reconstructive Surgery, vol. 90, no. 1, pp. 142–143,
1992.
[112] P. A. Van Der Eerden, P. J. F. M. Lohuis, A. A. M. Hart, W.
C. Mulder, and H. Vuyk, “Secondary intention healing after
excision of nonmelanoma skin cancer of the head and neck: sta-
tistical evaluation of prognostic values of wound characteristics
and final cosmetic results,” Plastic and Reconstructive Surgery,
vol. 122, no. 6, pp. 1747–1755, 2008.
[113] M. Kalavala and C. Mills, “Bloodroot: an ancient remedy in
modern times,” in British Journal of Dermatology, Blackwell,
Oxford, UK, 2007.
Evidence-Based Complementary and Alternative Medicine 11
[114] K. Krishnamurthy, C. Hoffman, and J. Del Priore, “Bloodroot
necrosis,” Journal of the American Academy of Dermatology, vol.
60, no. 3, supplement 1, p. AB44, 2009.
[115] J. Y. Petit, M. F. Avril, A. Margulis et al., “Evaluation of
cosmetic results of a randomized trial comparing surgery and
radiotherapy in the treatment of basal cell carcinoma of the
face,” Plastic and Reconstructive Surgery, vol. 105, no. 7, pp.
2544–2551, 2000.
[116] A.-M. Wennberg, O. Larko¨, and B. Stenquist, “Five-year results
of Mohs’ micrographic surgery for aggressive facial basal cell
carcinoma in Sweden,” Acta Dermato-Venereologica, vol. 79, no.
5, pp. 370–372, 1999.
[117] G. J. Huang andD. F. Penson, “Internet health resources and the
cancer patient,” Cancer Investigation, vol. 26, no. 2, pp. 202–207,
2008.
[118] A. Molassiotis and M. Xu, “Quality and safety issues of web-
based information about herbal medicines in the treatment of
cancer,”ComplementaryTherapies inMedicine, vol. 12, no. 4, pp.
217–227, 2004.
[119] “Composition of matter for the chemical fixation of diseased
tissue preparatory for surgical removal,” Google Patents, 1944.
[120] L. B. Trost and P. L. Bailin, “History of Mohs surgery,” Derma-
tologic Clinics, vol. 29, no. 2, pp. 135–139, 2011.
[121] R. S. Kalish, J. A. Wood, D. M. Siegel, V. N. Kaye, and N.
A. Brooks, “Experimental rationale for treatment of high-risk
human melanoma with zinc chloride fixative paste. Increased
resistance to tumor challenge in murine melanoma model,”
Dermatologic Surgery, vol. 24, no. 9, pp. 1021–1025, 1998.
[122] N. A. Brooks, “Fixed-tissue micrographic surgery in the treat-
ment of cutaneous melanoma: an overlooked cancer treatment
strategy,” Journal of Dermatologic Surgery and Oncology, vol. 18,
no. 11, pp. 999–1001, 1992.
[123] F. E. Mohs, “Chemosurgery for skin cancer: fixed tissue and
fresh tissue techniques,” Archives of Dermatology, vol. 112, no.
2, pp. 211–215, 1976.
[124] M. Braun III, “The case of Mohs’ surgery by the fixed-tissue
technique,” Journal of Dermatologic Surgery and Oncology, vol.
7, no. 8, pp. 634–640, 1981.
[125] S. Yanazume, H. Douzono, Y. Yanazume, K. Iio, and T. Douchi,
“New hemostatic method using Mohs’ paste for fatal genital
bleeding in advanced cervical cancer,” Gynecologic Oncology
Case Reports, vol. 4, pp. 47–49, 2013.
[126] N. Nakai, Y. Okuzawa, and N. Katoh, “Clinical usefulness of
Mohs’ chemosurgery for palliative purposes in patients with
cutaneous squamous cell carcinomawith risk factors or without
indication for surgery: three case reports,” The Journal of
Dermatology, vol. 42, no. 4, pp. 405–407, 2015.
[127] FDALetter TriHerba, http://www.fda.gov/ICECI/Enforcement-
Actions/WarningLetters/2008/ucm1048288.htm.
[128] A. Government, Black Salve, Red Salve and Cansema, Edited
by Department of Health and Ageing, Therapeutic Goods
Administration, 2012.
[129] “How toMake Black Salve (Cansema) for Yourself,” http://www
.blacksalveaustralia.com/.
[130] “Black Salve Use on Animals,” http://archive.apvma.gov.au/arc-
hive/news/2012/2012-02-10 black salve.php.
[131] G. P. Guy, S. R. Machlin, D. U. Ekwueme, and K. R. Yabroff,
“Prevalence and costs of skin cancer treatment in the U.S.,
2002–2006 and 2007–2011,” American Journal of Preventive
Medicine, vol. 48, no. 2, pp. 183–187, 2015.
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
